The authors demonstrated that PIM2/3, but not PIM1 inhibition could reverse the resistance (40) yet our data might suggest that rather than a combination of AZD4573 with pan-PIM inhibitor, single agent enitociclib could prevent or treat emergent resistance due to PIM3 overexpression, but confirmation in larger datasets would be required as well as supportive data from corresponding tumor tissue to match observations in blood samples. Here, PIM1 is linked to neoplasm.